anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

228,481-228,540 of 319,975

filter-aware
05
The slide emphasizes operational reality over theoretical development.Nikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations 1 hit
06
The slide highlights the 'Battery Electric 2.0' initiative and provides a competitive breakdown of HVIP voucher requests.Nikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
07
Includes map of California with refueling site markers and two photos of Nikola/HYLA refueling equipment.Nikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
08
The slide uses a circular process flow to illustrate the 'Build, Repeat' strategy.Nikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
09
Nikola | Results Presentation Deck | 18 slidesNikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
10
The slide presents two distinct financial tables side-by-side with qualitative commentary for each.Nikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
11
The slide uses a stacked bar chart to decompose unit costs into variable, fixed, and accrual components.Nikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations Beat · Satisfaction1 hit
12
Nikola | Results Presentation Deck | 18 slidesNikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations 1 hit
13
The table includes truck deliveries, revenue, gross margin, R&D, SG&A, stock-based compensation, and CapEx.Nikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations 1 hit
14
Nikola | Results Presentation Deck | 18 slidesNikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations 1 hit
15
Includes a footnote regarding regulatory and legal matters.Nikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations 1 hit
16
Includes a footnote regarding regulatory and legal matters.Nikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations 1 hit
17
The table reconciles GAAP cash flow components to the non-GAAP 'Adjusted free cash flow' metric.Nikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations 1 hit
18
The slide is a full-bleed image of a Nikola truck with the company logo in the bottom right corner.Nikola | Results Presentation Deck | 18 slides · Nikola
Conference presentation Investor relations 1 hit
01
Slide 1
Nuvalent | Investor Presentation Deck | 42 slidesNuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
02
Nuvalent | Investor Presentation Deck | 42 slidesNuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
03
The slide uses a 2x2 grid layout to summarize key company metrics.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
04
The slide uses a 'The Nuvalent Approach' framing to outline their core methodology.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
05
The slide uses a timeline-based structure to demonstrate operational momentum.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
06
The slide uses a timeline to show the progression from global strategy execution to product approval, complemented by a list of 2024 milestones.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
07
The slide uses a split layout with a left-hand sidebar for advisors/board and a right-hand grid for the leadership team.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
08
The slide uses a standard pharmaceutical pipeline visualization format.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
09
The slide highlights the lack of clear standard of care in later lines of therapy, framing the problem for a potential new therapeutic intervention.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Pattern Hunter1 hit
10
The slide uses a 'Case Study' framework to validate the strategy by comparing it to the established success of Osimertinib in EGFR+ NSCLC.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Pattern Hunter1 hit
11
The slide uses a bar chart to segment the $3.1B market into specific drugs and categories.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizeLoop · Pattern Hunter1 hit
12
The slide uses a sidebar 'AT A GLANCE' to summarize key product attributes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
13
The slide uses a timeline-based framework to map clinical stages (1L, 2L, 3L+) against standard therapies and unmet needs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
14
The slide uses a matrix-like structure to compare drug generations against clinical outcomes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
15
The slide uses a split-screen layout to contrast in vitro potency (dot plot) with in vivo efficacy (bar chart).Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
16
Includes a bar chart for brain penetrance and a dot plot for selectivity index across various mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
Includes detailed patient enrollment table by dose cohort and trial objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
18
Data cut-off: 8 Aug 2023. Includes detailed breakdown of prior ALK TKI lines and specific mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
19
Data from ALKOVE-1 Phase 1 trial, presented at AACR-NCI-EORTC 2023.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
20
The slide uses a standard oncology 'swimmer' or 'waterfall' plot format to demonstrate drug efficacy across different patient cohorts.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Cost Of Inaction1 hit
21
Swimmer plot showing patient-level treatment duration with ongoing status and response markers.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
22
Includes two patient case studies with MRI scans showing baseline vs follow-up results.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
23
Data cut-off: 8 Aug 2023. Source: Lin J.J. et al., AACR-NCI-EORTC 2023.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
24
The chart shows pharmacokinetic data across five dose cohorts, demonstrating that the 150mg dose consistently stays above the predicted CNS efficacy thresholds.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and map the drug's value proposition to each.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
26
Includes a detailed table of patient cohorts and study objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
27
The slide uses a sidebar 'AT A GLANCE' to summarize key clinical and regulatory status.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
28
The slide uses a timeline-based framework to contrast treatment options with clinical limitations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
29
The slide uses a matrix-like structure to compare NVL-520's clinical profile against five competitors (Crizotinib, Entrectinib, Lorlatinib, Repotrectinib, Taletrectinib).Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
30
Slide presents three distinct preclinical data sets: IC50 viability assays, brain:plasma ratio, and selectivity index vs TRKB.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
31
The slide presents a summary of a clinical trial, including patient eligibility criteria and a breakdown of patient cohorts by dose level.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
32
Data presented in two tables: Patient Characteristics and Treatment History.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
33
Includes a summary table of ORR and a waterfall plot of tumor regression.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
34
Includes specific patient subgroup metrics (ORR, tumor shrinkage) and longitudinal imaging.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
35
Data as of 13 Sep 2022. Includes list of specific adverse events by grade.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
36
RP2D = Recommended Phase 2 Dose; QD = once daily; MTD = Maximum Tolerated Dose.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
37
The slide uses a comparative structure to contrast the 2L+ (salvage) and 1L (frontline) market opportunities.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
38
The slide outlines a multi-cohort study design with specific patient populations (TKI-naive vs pre-treated) and objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
39
The slide uses a 'ribbon' or 'banner' layout on the right to highlight key product attributes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
40
The slide uses three distinct chart types to demonstrate the drug's efficacy and safety profile.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
41
The slide uses a timeline framework to connect current clinical program statuses to a future milestone.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
42
Nuvalent | Investor Presentation Deck | 42 slidesNuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
01
Slide 1
Includes company logo and date.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
02
Omnicell | Investor Presentation Deck | 27 slidesOmnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
03
The slide uses a circular crop for the image, which is a common design element in corporate presentations to soften the visual impact.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit
04
The slide uses a circular photo of two professionals working together to humanize the corporate mission statement.Omnicell | Investor Presentation Deck | 27 slides · Omnicell
Conference presentation Investor relations 1 hit